Anzeige
Meldung des Tages: Game Changer! Steht hier jetzt die strukturelle Neubewertung nach einem Strategiewechsel bevor?

Bavarian Nordic Aktie News

Aktie
WKN:  917165 ISIN:  DK0015998017 US-Symbol:  BVNKF Branche:  Biotechnologie Land:  Dänemark
26,56 €
+0,29 €
+1,10%
16:33:55 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,97 Mrd. €
Streubesitz
70,67%
KGV
15,06
neu: Nachhaltigkeits-Score
64 %
Index-Zuordnung
-

Bavarian Nordic News

18.06.25 - GlobeNewswire
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total ...
12.06.25 - GlobeNewswire
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX ...
09.05.25 - GlobeNewswire
Bavarian Nordic Announces Interim Results for the First Three Months of 2025
COPENHAGEN, Denmark , May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. ...
06.05.25 - GlobeNewswire
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines
Exercised options total USD 143.6 million Secures manufacturing and supply of freeze-​dried JYNNEOS ® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian ...
02.05.25 - GlobeNewswire
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom
COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...
16.04.25 - GlobeNewswire
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)
Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or elevated risk of chikungunya. ...
31.03.25 - GlobeNewswire
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-​dried ...
12.03.25 - GlobeNewswire
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual ...
07.03.25 - GlobeNewswire
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...
05.03.25 - GlobeNewswire
Bavarian Nordic Publishes Annual Report 2024
Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-​stage pipeline programs, Lyme disease and Epstein-​Barr Virus ...
28.02.25 - GlobeNewswire
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, ...
25.02.25 - GlobeNewswire
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-​income countries. ...
14.02.25 - GlobeNewswire
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial ...
03.02.25 - GlobeNewswire
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025
Travel Health business demonstrated strong growth of 22%. Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also ...
31.01.25 - GlobeNewswire
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-​like particle (VLP) single-​dose chikungunya vaccine is expected to launch in ...
16.09.24 - ARIVA.DE Redaktion
WHO erteilt grünes Licht für Mpox-Impfstoff von Bavarian Nordic
Die Weltgesundheitsorganisation (WHO) hat den Mpox-​Impfstoff von Bavarian Nordic, MVA-BN, für den weltweiten Einsatz präqualifiziert. Dies ermöglicht den Vereinten Nationen ...

Newssuche

Videos

newspaper
13:00 Uhr -6,03%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »